SANUWAVE, Inc. Health Submits to FDA First Module of PMA Application for dermaPACE for the Treatment of Diabetic Foot Ulcers

Published: Dec 10, 2010

ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTC BB: SNWV), an emerging medical technology company focused on regenerative medicine, today reported its submission to the U.S. Food and Drug Administration (FDA) of the first module of the Premarket Approval (PMA) application for the Company’s dermaPACE™ device for the treatment of diabetic foot ulcers (DFU).

Back to news